Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by prophetoffactzon Aug 15, 2024 2:02pm
105 Views
Post# 36181048

RE:RE:RE:New Press Release - Microbix Reports Continued Strong Results for Q3 Fiscal 2024

RE:RE:RE:New Press Release - Microbix Reports Continued Strong Results for Q3 Fiscal 2024With sizable interest rate cuts after 40 year high inflation and very sharp interest rate hikes off the zero-bound as well as expected 20-40% growth next year and consistent progress with Kinlytic the next 12 months are poised to be a breakout year.   

lscfa wrote:

 

Antigen + QAP

Qtr ending 

Antigen

QAP

4,946,122

Jun 24

3,276,469

1,669,653

5,511,058

Mar 24

4,111,462

1,399,596

4,201,913

Dec 23

1,953,677

2,248,236

4,172,410

Sep 23

2,977,179

1,195,231

4,065,426

Jun 23

2,608,521

1,456,905

4,106,414

Mar 23

3,004,730

1,101,684

2,337,310

Dec 22

1,003,807

1,333,503

4,231,801

Sept 22

2,629,901

1,601,900

3,589,517

Jun 22

2,283,621

1,305,896

2,926,352

Mar 22

1,607,970

1,318,382

2,915,567

Dec 21

1,766,416

1,149,151

3,216,406

Sep 21

2,020,861

1,195,545

3,450,586

Jun 21

2,398,969

1,051,617

4,019,451

Mar 21

2,524,363

1,495,088

3,100,250

Dec 20

2,137,829

962,421

 



<< Previous
Bullboard Posts
Next >>